What is claimed is:

1. A compound of the formula (I)



(I)

wherein

R_1 and R_2 are, independently of one another,

1.0 H or

2.0 a -O-C_1-C_6-alkyl, -O-C_2-C_6-alkenyl, -O-C_2-C_6-alkynyl or -O-C_6-C_{10}-aryl group, in which alkyl, alkenyl and alkynyl are straight-chain or branched, and in which the alkyl, alkenyl and alkynyl groups are optionally mono- or disubstituted by:

2.1 –OH,

2.2 =O,

2.3 –O-C_1-C_6-alkyl in which alkyl is straight-chain or branched,

2.4 –O-C_2-C_6-alkenyl in which alkenyl is straight-chain or branched,

2.5 – C_6-C_{10}-aryl,

2.6 –NH-C_1-C_6-alkyl in which alkyl is straight-chain or branched,

2.7 –NH-C_2-C_6-alkenyl in which alkenyl is straight-chain or branched,

2.8 –NH_2 or

2.9 halogen,

and in which the aryl groups are optionally mono- or disubstituted by substituents 2.1 or 2.3 to 2.9,

in which the substituents 2.3, 2.4, 2.6 and 2.7 may be further substituted by -CN, -amide or -oxime functions, and 2.5 may be further substituted by –CN or amide functions

or

R_1 and R_2 together form a group -O-[(C_1-C_6)-alkylene]-O-,

R_3 is

1.0 H or

2.0 a C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl or C_6-C_{10}-aryl group, in which alkyl, alkenyl and alkynyl are straight-chain or branched, and in which the alkyl, alkenyl and alkynyl groups are optionally mono- or disubstituted by:

2.1 –OH,

2.2 =O,

2.3 –O-C_1-C_6-alkyl in which alkyl is straight-chain or branched,

2.4 –O-C_2-C_6-alkenyl in which alkenyl is straight-chain or branched,

2.5 – C_6-C_{10}-aryl,

2.6 –NH-C_1-C_6-alkyl in which alkyl is straight-chain or branched,

2.7 –NH-C_2-C_6-alkenyl in which alkenyl is straight-chain or branched,

2.8 –NH_2 or

2.9 halogen,

and in which the aryl groups are optionally mono- or disubstituted by substituents 2.1 or 2.3 to 2.9,

in which the substituents 2.3, 2.4, 2.6 and 2.7 may be further substituted by -CN, -amide or -oxime functions, and 2.5 may be further substituted –CN or amide, and

R_4 is

CO_2R_3, CO_2NHR_3, CHO, CH_2OR_3, $CH_2OSi(R_3)_3$, CH_2Br, CH_2CN, where R_3 is as defined above,

or a stereoisomeric form of the compound of the formula (I) or a physiologically tolerated salt of the compound of the formula (I) or a salt of a stereoisomeric form of the compound of the formula(I).

2. The compound according to claim1, which is the compound of formula (II)



(II).

3. The compound according to claim1, which is the compound of formula (III)



(III).

4. The compound according to claim1, which is the compound of formula (IV)



(IV).

5. A process for the preparation of the compound of formula (I), according to claim 1 comprising:

1. extracting the plant *Beilschmiedia fulva*, PLA 101037, or cell cultures of the plant *Beilschmiedia fulva*, PLA 101037, under suitable conditions,
2. isolating the compound of the formula (IV),



(IV), and

3. where appropriate derivatizing to a compound of the formula (I) and/or reacting to give a physiologically tolerated salt of the compound of the formula (I).

6. A process for the preparation of the compound of formula (IV) according to claim 4 comprising:

1. extracting the plant *Beilschmiedia fulva*, PLA 101037, or cell cultures of the plant *Beilschmiedia fulva*, PLA 101037, under suitable conditions,
2. isolating the compound of the formula (IV), and
3. where appropriate reacting to give a physiologically tolerated salt of the compound of the formula (IV).

7. A pharmaceutical composition comprising a compound of claim 1 or a pharmacologically tolerable salt thereof and one or more physiologically acceptable excipients.

8. A process for the preparation of a pharmaceutical composition as claimed in claim 7, comprising bringing a compound of formula (I), or a pharmacologically tolerable salt thereof, into a suitable administration form using one or more physiologically suitable excipients.

9. A method of inhibiting c-maf and NFAT to treat a disease or disorder which comprises administering to a patient in need of said treatment or disorder an effective c-maf and NFAT inhibitory amount of a compound according to claim 1.

10. The method according to claim 9 wherein the disease or disorder is selected from the group consisting of allergies, asthma and inflammatory symptoms associated with asthma.